Novo Nordisk Stock Analysis

News

CEO of Novo Nordisk, maker of weight loss drug Wegovy

Can a new CEO fix Novo Nordisk's problems? This analyst says no.

Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination with Josh Lipton and Bullseye American Ingenuity Fund portfolio manager Adam Johnson to discuss the surprise C-suite change.

GlobalData on MSN · 1d

Novo Nordisk’s CEO to step down as weight loss market share plummets

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of leadership was required amid fierce glucagon-like peptide 1 receptor agonists (GLP-1RA) market pressure from Eli Lilly.

Barron's on MSN · 13d

Novo Nordisk Cuts Guidance as Weight-Loss Drug Sales Slow. Why the Stock Is Up.

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cuts its guidance for the year. For the full year, the company now expects sales growth between 13% and 21%.

13hon MSN

Why Novo Nordisk Stock Popped on Tuesday

Novo Nordisk ( NVO 1.82%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...

Ignore The Noise - Novo Nordisk Is A Clear Buy

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

4don MSN

Novo Nordisk to replace CEO Lars Jorgensen amid stiff competition in obesity drug market; stock down 33% YTD

The Novo Nordisk Foundation started a dialog with Novo’s board “on the merits of an accelerated CEO succession,” Novo said, ...

4don MSN

Why Novo Nordisk Stock Just Slipped

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk, Charter & Cox, Take Two: Trending Tickers

CEO Lars Fruergaard Jørgensen is set to step down. Charter (CHTR) and Cox Communications announce a merger in a $34.5 billion deal. Take Two (TTWO) forecasts weak 2026 bookings as the delayed release ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results